Evidence map›Paper›PMID 40100379›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Overexpression of KIF2C amplifies tamoxifen resistance and lung metastasis of breast cancer through PLK1/C-Myc pathway.

Rui Tian, Jilin Kong, Hongyan Zang, Shuyan Li, Xiangjuan Liu, Yan Cheng, Gaofeng Ni, Liguo Gong

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rui TianDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Jilin KongDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Hongyan ZangDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Shuyan LiDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Xiangjuan LiuDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Yan ChengDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Gaofeng NiDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China.
Liguo GongDepartment of Breast Surgery, Yantaishan Hospital, No. 10087 Keji Road, Laishan District, Yantai, 264000, Shandong, China. gongliguo0859@163.com.

Funding

Application for Policy Guidance Projects of Yantai Science and Technology Innovation Development Plan in 2023 2023YD012
6 · The paper itself

Abstract

We highlighted the importance of KIF2C in the development of resistance to tamoxifen and its role in promoting lung metastasis in breast cancer, as well as the mechanisms that underpin these processes. KIF2C overexpression and knockdown lentiviruses were transfected into MCF-7 and MCF-7/TAM cells. A nude mouse model of MCF-7/TAM tumors and lung metastasis was established. The PLK1 inhibitor BI2536 was used to explore the underlying mechanism. KIF2C is elevated in tamoxifen-resistant breast cancer. KIF2C knockdown MCF7/TAM cells show increased sensitivity to tamoxifen, indicated by fewer cell clones, invasive cells, migration area, and lumen count, as well as a higher rate of cell apoptosis. KIF2C is linked to the PLK1/c-Myc signaling pathway, and BI2536 inhibits its enhancement of tamoxifen resistance. Results from an in situ experiment on breast cancer in mice are consistent with in vitro findings. KIF2C upregulation is linked to greater tamoxifen resistance in breast cancer, facilitating progression and lung metastasis in resistant cases. KIF2C's potential mechanism of action is linked to the PLK1/c-Myc signaling pathway.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsCell Cycle ProteinsDrug Resistance, NeoplasmKinesinsLung NeoplasmsProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-mycTamoxifenAnimalsFemaleHumansMCF-7 CellsMiceMice, Inbred BALB CAntineoplastic Agents, HormonalBI 2536Cell Cycle ProteinsKinesinsMYC protein, humanPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-mycPteridinesTamoxifenBreast cancerKIF2CLung metastasisPLK1/c-Myc pathwayTamoxifen resistance

Identifiers

PMID40100379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.